Vascodagama Online Journal

Choroidal Neovascularization Market Is Anticipated To Grow During the Forecast Period (2022-2032)

 Breaking News
  • No posts were found

Choroidal Neovascularization Market Is Anticipated To Grow During the Forecast Period (2022-2032)

March 21
03:16 2023
Choroidal Neovascularization Market Is Anticipated To Grow During the Forecast Period (2022-2032)

The growth of the Choroidal Neovascularization Market is a direct result of rising activity, an ageing population, and the anticipated commercial success of new treatments in the 7MM.


The Choroidal Neovascularization market report provides current treatment practices, emerging drugs, Choroidal Neovascularization market share of the individual therapies, current and forecasted Choroidal Neovascularization market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Choroidal Neovascularization treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Choroidal Neovascularization market.


Key takeaways from the Choroidal Neovascularization Market Research Report


  • According to DelveInsight, the Choroidal Neovascularization Market in 7MM is expected to witness a major change in the study period 2019-2032


  • As per the study conducted by Wong TY et al. (2014), the Incidence of CNV in individuals with pathologic myopia was reported to be 2%-11.3%, and was bilateral in approximately 15% of patients.


  • Choroidal Neovascularization Market Companies include Roche, Regeneron Pharmaceuticals, Adverum Biotechnologies, Iconic Therapeutics, and others.


  • Choroidal Neovascularization Market Therapies include ICON-1, ADVM-022, Eylea, Lucentis, and others 


Find out which treatments are anticipated to have a big Market Size for Choroidal Neovascularization Market Report @ Choroidal Neovascularization Market Size


Choroidal Neovascularization Overview

 Choroidal neovascularization involves the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the sub–retinal pigment epithelium (sub-RPE) or Subretinal space. CNV is a major cause of visual loss. The symptoms of CNV include a distortion or waviness of central vision or a gray/black/void spot in the central vision.


Choroidal Neovascularization Epidemiology Insights

The epidemiology section covers insights into the historical and current Choroidal Neovascularization Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Download the report to understand which factors are driving Choroidal Neovascularization epidemiology trends @ Choroidal Neovascularization Epidemiological Insights


Choroidal Neovascularization Market Size

The Choroidal Neovascularization market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Choroidal Neovascularization Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period. The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Choroidal Neovascularization Market size by analyzing the impact of current and emerging therapies in the market.


Choroidal Neovascularization Market Insights

Choroidal Neovascularization is most commonly found in people age 50 and older. The risk grows with age. This is because wet age-related macular degeneration accounts for most patients with CNV. “Neovascularization” means “new blood vessels.” These new, abnormal blood vessels originate in the choroid, a vessel-containing layer under the retina. When the retinas of people with AMD produce too much vascular endothelial growth factor (VEGF), new blood vessels sprout from the choroid, then grow into the retina. The new vessels, unlike normal ones, are leaky, and they allow fluid from the blood, and sometimes even red blood cells, to enter the retina. This fluid can immediately distort the vision because it forms a “blister” in the retina, which is normally flat. Over the course of days to months, this fluid can damage the retina, killing the light-sensing cells, called photoreceptors.


Choroidal Neovascularization Treatment Market

Choroidal Neovascularization treatment can vary depending on the underlying disease. The management of CNV was developed through laser photocoagulation and photodynamic therapy, and has now evolved into anti-vascular endothelial growth factor (VEGF) use. Patients have achieved better visual acuity and toleration with the development of this therapy strategy. Combination therapy appears to offer a reduced retreatment frequency and long-term maintenance of the benefit with appropriate combination. Other treatment explorations with anti-inflammation and anti-VEGF are also ongoing.


Choroidal Neovascularization Market Dynamics

The Choroidal Neovascularization market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2022–2032.


Download the report to understand which factors are driving the Choroidal Neovascularization Treatment Market Report @ Choroidal Neovascularization Clinical Trials Analysis


Scope of the Choroidal Neovascularization Market Forecast Report

  • Coverage- 7MM
  • Choroidal Neovascularization Market Companies- Roche (NYSE: RHHBY), Regeneron Pharmaceuticals (NYSE: REGN), Adverum Biotechnologies (NYSE: ADVN), Iconic Therapeutics, and many others
  • Choroidal Neovascularization Pipeline Therapies- ICON-1, ADVM-022, Eylea, Lucentis, and many others
  • Choroidal Neovascularization Market Dynamics: Choroidal Neovascularization Market Drivers and Barriers


Got Queries? Reach out for more information of the Choroidal Neovascularization Market Companies @ Choroidal Neovascularization Market Drivers and Barriers


Table of Content

1. Key Insights

2. Choroidal Neovascularization Executive Summary

3. Competitive Intelligence Analysis for Choroidal Neovascularization

4. Choroidal Neovascularization: Market Overview at a Glance

5. Choroidal Neovascularization: Disease Background and Overview

6. Patient Journey

7. Choroidal Neovascularization Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Choroidal Neovascularization Unmet Needs

10. Key Endpoints of Choroidal Neovascularization Treatment

11. Choroidal Neovascularization Marketed Products

12. Choroidal Neovascularization Emerging Therapies

13. Choroidal Neovascularization: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Choroidal Neovascularization Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Choroidal Neovascularization Market Drivers

19. Choroidal Neovascularization Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Get in touch with our Business Consultant @ Choroidal Neovascularization Market Forecast Report


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States